biotas open briefing, page-11

I think TJW would probably give you a better answer than me, but one reason I can think of, is that it would give Biota the freedom to quide the direction of Relenza and receive all the benefits, whereas now they have licensed it to GSK there involvement is limited, for instance it should have been repackaged with an easier to use Inhaler and easier packaging for stockpiling and Biota do not have control of this.

It was in Biota,s briefing they mentioned IP (International Property) with the CSIRO? Maybe it is worth Billions when they are only receiving Millions??

TJW said a few months ago............... GSK would not give back the Patent as they had spent 200 Million dollars on it.........your guess is as good as mine?

Cheers dma